Medline Inc.
NASDAQ:MDLN · NASDAQ Global Select
-$0.42 today
Vol 13.95M · Avg 9.27M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:MDLN · Revenue to Net Income
Key Ratios
Analysis
$29.1B of revenue converted into $964.0M of net income for the selected period. Gross margin is 24.1% and net margin is 3.4%, showing how much revenue survives after costs and taxes. EPS is $1.21, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $28.4B +11.5% | $25.5B +9.8% | $23.2B +8.3% | $21.4B | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $20.9B +8.8% | $19.2B +6.7% | $18.0B +6.6% | $16.9B | $344.8M | $725.6M | $804.0M |
| Gross Profit | $7.5B +19.5% | $6.3B +20.4% | $5.2B +14.6% | $4.6B | $10.3B | $8.9B | $7.6B |
| Gross Margin | 26.4% +1.8pp | 24.7% +2.2pp | 22.5% +1.2pp | 21.2% | 45.5% | 9.8% | 28.9% |
| Research & Development | $0 -100.0% | $67.0M +11.7% | $60.0M +3.4% | $58.0M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $4.5B +12.0% | $4.0B +6.1% | $3.8B +5.2% | $3.6B | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $5.3B +30.5% | $4.1B +7.6% | $3.8B +2.5% | $3.7B | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $704.0M -27.9% | $977.0M +2.7% | $951.0M +1.9% | $933.0M | $1.2B | $374.2M | $1.2B |
| EBITDA | $2.0B -44.7% | $3.5B +36.4% | $2.6B +39.7% | $1.9B | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 6.9% -7.0pp | 13.8% +2.7pp | 11.1% +2.5pp | 8.6% | 10.0% | 5.6% | 46.3% |
| Operating Income | $2.2B -0.6% | $2.2B +54.1% | $1.4B +66.0% | $870.0M | $10.6B | $12.3B | $14.0B |
| Operating Margin | 7.8% -0.9pp | 8.7% +2.5pp | 6.2% +2.2pp | 4.1% | 18.7% | 16.6% | 24.1% |
| Interest Income | $0 -100.0% | $280.0M +18.1% | $237.0M +777.8% | $27.0M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $812.0M -38.0% | $1.3B -4.8% | $1.4B +50.9% | $911.0M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$964.0M +1.5% | -$979.0M +17.0% | -$1.2B -37.2% | -$860.0M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $1.2B +0.2% | $1.2B +372.0% | $264.0M +2540.0% | $10.0M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 4.4% -0.5pp | 4.9% +3.7pp | 1.1% +1.1pp | 0.0% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $91.0M +97.8% | $46.0M +53.3% | $30.0M -14.3% | $35.0M | $666.8M | $1.3B | -$1.6B |
| Net Income | $1.2B -3.4% | $1.2B +412.8% | $234.0M +1036.0% | -$25.0M | $5.0B | $4.9B | $4.8B |
| Net Margin | 4.1% -0.6pp | 4.7% +3.7pp | 1.0% +1.1pp | -0.1% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $1 -5.9% | $2 +406.7% | $0 +1043.4% | -$0 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $1 -5.9% | $2 +406.7% | $0 +1043.4% | -$0 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $812.0M +3.2% | $787.1M +0.0% | $787.1M +0.0% | $787.1M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $812.0M +3.2% | $787.1M +0.0% | $787.1M +0.0% | $787.1M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ResMed Inc.
NYSE:RMD
$27.26B
The Cooper Companies, Inc.
NASDAQ:COO
$12.85B
Avantor, Inc.
NYSE:AVTR
$6.54B
Bausch + Lomb Corporation
NYSE:BLCO
$5.32B
Netskope, Inc. Class A Common Stock
NASDAQ:NTSK
$3.61B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.13B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.17B
Lumexa Imaging Holdings, Inc. Common Stock
LMRI
$887.79M
InfuSystem Holdings, Inc.
AMEX:INFU
$186.28M
Black Rock Coffee Bar, Inc. Class A Common Stock
NASDAQ:BRCB
$136.95M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MDLN generate?
Medline Inc. (MDLN) reported $28.43B of revenue in fiscal 2025.
Is MDLN profitable?
Medline Inc. (MDLN) reported $1.16B of net income, with a net margin of 4.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.